Studies on Disease-Modifying Antirheumatic Drugs. II. Synthesis and Activity of the Metabolites of Ethyl 4-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603).
作者:Atsuo BABA、Haruhiko MAKINO、Yoshikazu OHTA、Takashi SOHDA
DOI:10.1248/cpb.46.1130
日期:——
The metabolites of ethyl 4-(3, 4-dimethoxyphenyl)-6, 7-dimethoxy-2-(1, 2, 4-triazol-1-ylmethyl)quinoline-3-carboxylate (1, TAK-603), which is under clinical evaluation as a new type of disease-modifying antirheumatic drug (DMARD), were prepared to confirm their structures and to study their pharmacological properties. Of the metabolites identified, the 4-(4-hydroxy-3-methoxyphenyl) derivative (2c, M-I) was found to have an anti-inflammatory effect in an adjuvant arthritic rat model, although its potency in this model was slightly lower than that of the parent compound.
我们制备了 4-(3,4-二甲氧基苯基)-6,7-二甲氧基-2-(1,2,4-三唑-1-基甲基)喹啉-3-羧酸乙酯(1,TAK-603)的代谢物,以确认其结构并研究其药理特性。在鉴定出的代谢物中,发现 4-(4-羟基-3-甲氧基苯基)衍生物(2c,M-I)在佐剂关节炎大鼠模型中具有抗炎作用,尽管其在该模型中的效力略低于母体化合物。